|
Big Ten CRC News & Events
|
|
Big Ten CRC kidney cancer study published in JCO
Big Ten CRC researchers recently reported in the
Journal of Clinical Oncology that the combination of pembrolizumab and bevacizumab is safe and active in patients with metastatic kidney cancer. "Our study demonstrated that pembrolizumab and bevacizumab can control metastatic kidney cancer for more than 20 months in the majority of patients treated," said sponsor-investigator
Arkadiusz Z. Dudek, MD, a professor in the Division of Hematology/Oncology, Department of Medicine, at the University of Illinois at Chicago, and medical oncologist at HealthPartners Regions Cancer Care Center in St. Paul, Minn.
|
|
Joshi presents early safety, efficacy data from bladder study
Monika Joshi, MD, MRCP, associate professor of medicine at Penn State Hershey Cancer Institute, presented a poster that highlighted early safety and efficacy data from the Big Ten Cancer Research Consortium's BTCRC-GU15-023 study during the American Society of Clinical Oncology's 2020 Genitourinary Cancers Symposium on Feb. 14 in San Francisco, Calif. The phase Ib/II study is testing concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with urothelial cancer (T2-4 N0-2 M0) of the bladder.
|
|
Big Ten CRC appoints new Steering Committee leadership
The Big Ten Cancer Research Consortium recently appointed
Kari B. Wisinski, MD, associate professor of hematology/oncology, Department of Medicine at University of Wisconsin School of Medicine and Public Health, as chair of the consortium's Steering Committee.
Peter G. Shields, MD, deputy director, The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), will serve as vice chair of the Steering Committee for one year and as chair the following year.
|
|
Lao represents University of Michigan on Steering Committee
Christopher Lao, MD, was recently appointed to represent the University of Michigan Rogel Cancer Center on the Big Ten Cancer Research Consortium Steering Committee. Dr. Lao is clinical professor of internal medicine - hematology/oncology, and medical director of clinical trials for oncology at the University of Michigan. "The Big Ten CRC is an opportunity to run multi-institutional trials that are important," Dr. Lao said. "Having multiple collaborators involved makes these trials more efficient and provides high-quality data, which will ultimately lead to changing practice and greater support for our patients."
|
|
Indiana University
Investigator Spotlight
In a recent investigator spotlight,
Anita Turk, MD, writes, "my research focus is to develop targeted and immune-based therapies for my patients. Through Indiana University's Precision Genomics Clinic, we have been able to sequence tumors to help us understand the biology and identify the best clinical trials within the Big Ten CRC for our patients.
Read more.
|
|
Thought Leader Perspective
Patrick J. Loehrer, Sr., MD, director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, reflects on four decades of progress at the cancer center - from Larry Einhorn, MD's discovery of the cure for testicular cancer in 1974, to the cancer center's recent comprehensive cancer center designation by the National Cancer Institute.
Read more.
|
|
Penn State Cancer Institute
Featured Member
Penn State Cancer Institute has three research programs focused on the themes of Population Health and Cancer Control, Mechanisms of Carcinogenesis, and Experimental Therapeutics. Additionally, pediatric cancer research led by faculty at Penn State Children's Hospital and Penn State College of Medicine is a highly visible part of the Penn State Cancer Institute and greatly benefits from THON and Four Diamonds.
Read more.
|
|
